Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

3.9K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

726
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
726
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

367
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
367
Teratogenicity01:07

Teratogenicity

4.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.3K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

451
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
451
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

641
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
641

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contrastive Machine Learning to Quantify Hypertensive Multiorgan Damage and Identify New Disease Phenotypes: A Multinational Multimodal Study.

Circulation·2026
Same author

Normative volumetric growth modeling of the whole fetal body, placenta, and amniotic fluid for three-dimensional T2-weighted magnetic resonance imaging.

Pediatric radiology·2026
Same author

The contribution of the antenatal period in the development of necrotising enterocolitis.

Early human development·2026
Same author

Impacted fetal head: a retrospective cohort study of full dilatation caesarean section.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Evaluating glycosylated fibronectin for rule-in and rule-out of pre-eclampsia in suspected cases.

Pregnancy hypertension·2026
Same author

Late preterm birth: how big is the problem?

European journal of obstetrics, gynecology, and reproductive biology·2026

Related Experiment Video

Updated: Feb 22, 2026

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.4K

Preterm pre-eclampsia: What every neonatologist should know.

Lisa Story1, Lucy C Chappell2

  • 1Centre for the Developing Brain, Faculty of Life Sciences and Medicine, King's College London, SE1 7EH, United Kingdom; Department of Women and Children's Health, Faculty of Life Sciences and Medicine, King's College London, London SE1 7EH, United Kingdom.

Early Human Development
|September 18, 2017
PubMed
Summary
This summary is machine-generated.

Pre-eclampsia, a pregnancy complication affecting 5-10% globally, lacks a cure besides delivery. Current predictive tests have limited clinical use due to suboptimal performance, impacting maternal and infant outcomes.

Keywords:
Fetal growth restrictionHypertensionPre-eclampsiaPregnancy

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.9K
Preterm EEG: A Multimodal Neurophysiological Protocol
19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

29.1K

Related Experiment Videos

Last Updated: Feb 22, 2026

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.4K
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.9K
Preterm EEG: A Multimodal Neurophysiological Protocol
19:32

Preterm EEG: A Multimodal Neurophysiological Protocol

Published on: February 18, 2012

29.1K

Area of Science:

  • Obstetrics and Gynecology
  • Perinatal Medicine
  • Maternal-Fetal Medicine

Background:

  • Pre-eclampsia is a significant global pregnancy complication (5-10% of pregnancies) leading to considerable maternal and perinatal morbidity and mortality.
  • Currently, the only definitive treatment for pre-eclampsia is delivery, highlighting the need for effective management strategies.
  • Existing predictive screening tests, utilizing clinical factors, biomarkers, and imaging, face limited clinical adoption due to suboptimal performance.

Purpose of the Study:

  • To review the current landscape of pre-eclampsia management.
  • To discuss the challenges in predictive screening and clinical adoption.
  • To highlight the impact of pre-eclampsia and associated fetal growth restriction on infant outcomes.

Main Methods:

  • Literature review of pre-eclampsia screening, diagnosis, and management.
  • Analysis of factors influencing clinical practice adoption of predictive tests.
  • Examination of the relationship between pre-eclampsia, fetal growth restriction, and perinatal outcomes.

Main Results:

  • Suboptimal performance of current predictive screening tests limits their clinical utility.
  • Expectant management is standard for diagnosed pre-eclampsia before 37 weeks to balance risks of prematurity against benefits of pregnancy continuation.
  • Fetal growth restriction, common in early-onset pre-eclampsia, significantly influences delivery decisions and neonatal prognosis.

Conclusions:

  • There is an unmet need for improved predictive screening tests for pre-eclampsia to enhance clinical adoption.
  • Effective management of pre-eclampsia requires careful consideration of maternal and fetal well-being, especially concerning prematurity and growth restriction.
  • Both prematurity and fetal growth restriction associated with pre-eclampsia have significant short- and long-term consequences for infants.